Genetic Technologies Ltd (ASX: GTG) Share Price and News

Mr. Burrows has over 30 years' of experience .He is a independent Non-Executive Director across the Listed, government and private sectors with expertise in corporate governance, and strategic, commercial, financial and risk management oversight, underpinned by his background as a chartered accountant. Mr. Burrows was Chief Financial Officer and Company Secretary of Tassal Group Limited for 21 years from 1988 to 2009, and accordingly brings to the Board independent C suite commercial experience and the benefits of an senior executive ASX200 listed entity background. Mr Burrows current and past Board and advisory portfolio encompasses listed and regulated entities, government business enterprises, state-owned and local government entities and authorities, large private/ family companies community organizations, membership-based bodies and Not-for-Profits. Mr Burrows' expertise spans a raft of industry sectors encompassing water and sewerage, infrastructure, renewable energy, forestry, agribusiness, public transport, tourism and hospitality, education and the vocational education sector, aquaculture, civil engineering, construction, and finance and valuations.

Dr Wakefield started Safetech Pty Ltd in 1985 and over the next 25 years, Safetech became a force in the Australian material handling and lifting equipment market, designing and manufacturing a range of industrial products. In 1993, he left medicine to become the full time CEO of Safetech. In 2006, Safetech was awarded the Telstra Australian National Business of the Year. In 2013, Safetech merged and ultimately acquired Tiemen Materials Handling. Dr Wakefield continues as the CEO of Safetech. It is Australia's largest manufacturer and supplier of dock equipment, freight hoists and custom lifting solutions. Safetech employs approximately 100 people. Dr Wakefield has been a biotech investor for more than 20 years

Dr Muchnicki acted as Interim Chief Executive Officer from September 2019 till the appointment of Mr. Simon Morriss to the role. For the past 14 years, he has been involved in commercialization and funding R&D in the biotechnology sector from gene silencing to regenerative medicine. Dr Muchnicki brings with him commercial and medical skills, including broad interests in software development, blockchain and sustainable building materials. He is a co-founder and Non-Executive Director of Speed Panel Holdings a world leader in fire rated and acoustic wall solutions. He is also the co-founder of Candlebets, a software development company that is creating blockchain enabled platforms for the gaming industry.

Mr Rubinstein has over 20 years' experience in early-stage technology commercialization through to public listings on the ASX. He is a lawyer, having worked at a national firm prior to moving in-house at Montech, the commercial arm of Monash University. Mr. Rubinstein has had exposure to the creation, launch and management of a diverse range of technology companies in biotech, digital payments and renewable energy.

-

-

-

-

-

-

-

-

-

-